Mai Tran, PharmD, is a compounding pharmacist and Director of Sales, Marketing, and Clinical Education at Harbor Compounding Pharmacy. She earned her Doctor of Pharmacy degree from the University of the Pacific Thomas J. Long School of Pharmacy and has over a decade of experience specializing in individualized hormone replacement therapy (HRT), women's health, and compounded pharmaceutical formulations.
Throughout her career, Mai has collaborated with healthcare providers and Harbor's compounding team to develop personalized therapies addressing unmet clinical needs, including innovative oxytocin formulations for applications in women's sexual health. Her expertise encompasses bioidentical HRT, reproductive hormone physiology, and the clinical application of compounded therapies.
In 2020, Mai founded Harbor Academy, an educational initiative through which she has personally trained 500+ healthcare providers in hormone therapy dosing, monitoring, and individualized treatment strategies.
Mai also serves as a volunteer Clinical Educator and Clinical Advisory Board member for the Women's Hormone Network, contributing to provider education on Physiologic Hormone Restoration Therapy (PHRT) and women's hormonal health. Her work focuses on bridging reproductive physiology, emerging research, and clinical experience to advance individualized approaches to women's healthcare.
Expanding the Toolkit: Pharmaceutical Approaches to Women's Sexual & Genitourinary Health
Day & Time TBD
Women's sexual and genitourinary disorders encompass a broad spectrum of conditions that can significantly affect sexual desire, arousal, orgasm, intimacy, and quality of life. Despite their prevalence, these concerns are often underrecognized, undertreated, or challenging to manage with conventional approaches alone.
This presentation examines pharmaceutical strategies for addressing hypoactive sexual desire, orgasmic dysfunction, painful intercourse, vulvodynia, pelvic floor-related sexual pain, vulvar inflammatory disorders, and genitourinary symptoms associated with menopause. Emphasis will be placed on both commercially available medications and compounded therapies, including systemic, topical, intravaginal, and other specialized delivery methods.
Through a clinically focused review of established and emerging interventions, attendees will explore therapeutic mechanisms, published clinical evidence, formulation considerations, treatment limitations, and safety considerations. Particular attention will be given to differentiating treatments supported by clinical trials from off-label and investigational approaches, as well as identifying situations in which individualized pharmaceutical strategies may be appropriate.
Designed for practicing clinicians, this session will provide practical insights to broaden therapeutic options and support evidence-informed, patient-centered management of women's sexual and genitourinary health.
After the presentation, participants will be able to confidently:
Differentiate common female sexual and genitourinary disorders, including hypoactive sexual desire disorder, genito-pelvic pain/penetration disorders, female orgasmic disorder, genitourinary syndrome of menopause, and vulvar lichen sclerosus, to guide appropriate pharmaceutical treatment selection.
Compare the mechanisms of action, clinical efficacy, and safety profiles of conventional, compounded, and emerging pharmaceutical interventions used to manage women's sexual and genitourinary disorders.
Evaluate available clinical evidence supporting pharmaceutical therapies, distinguishing established treatments from off-label and investigational approaches.
Apply evidence-informed prescribing principles to select and individualize pharmaceutical interventions based on patient presentation, therapeutic goals, treatment response, and safety considerations.
ON DEMAND: The Interplay of Estrogen, Progesterone, Testosterone, and Oxytocin in Women's Sexual Desire
Day & Time TBD
Why do some women continue to experience hypoactive sexual desire disorder (HSDD) despite menopausal hormone therapy or testosterone supplementation? Conventional treatment approaches often emphasize low-dose estrogen, progestogen therapy, or testosterone supplementation, yet may not fully account for the complex hormonal interactions influencing female sexual desire.
This presentation challenges clinicians to reconsider conventional hormone dosing strategies by examining how estradiol, progesterone, and testosterone influence oxytocin synthesis, receptor expression, and signaling. Particular attention will be given to estrogen's potential facilitatory effects, progesterone's inhibitory effects, and the limitations of relying on testosterone without adequately evaluating estrogen status.
Drawing from reproductive physiology, experimental research, human clinical studies, and clinical observations, this lecture will explore whether reassessing estrogen dosing, minimizing unnecessary progesterone exposure while maintaining endometrial protection, and taking a more selective approach to testosterone therapy may offer a more comprehensive strategy for managing HSDD. The potential therapeutic role of exogenous oxytocin will also be examined, including its proposed mechanisms, clinical evidence, and limitations. Attendees will gain insight into how these interconnected hormonal pathways may inform individualized treatment strategies for female sexual desire.
After the presentation, participants will be able to confidently:
Describe the roles of estrogen, progesterone, testosterone, and oxytocin in the neuroendocrine regulation of female sexual desire.
Explain how reproductive hormones influence oxytocin synthesis, receptor expression, and signaling, and their potential implications for hypoactive sexual desire disorder (HSDD).
Analyze the potential effects of estrogen, progesterone, and testosterone dosing strategies on female sexual desire and the management of HSDD.
Evaluate current clinical evidence, emerging research, and limitations of hormonal and oxytocin-based interventions for HSDD.

